Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.
Journal of immunology (Baltimore, Md. : 1950) Jan, 2010 | Pubmed ID: 19995900